Close
Find out about Professor Amit Nathwani's research on regenerative medicine.
Molecular ‘reprogramming’ of adult somatic cells into induced pluripotent stem cells (iPS cells) raises possibilities for new cellular therapies.
We are developing iPS-derived retinal pigmented epithelium (RPE) to treat dry AMD (in collaboration with Prof Pete Coffey – Institute of Ophthalmology). Age-related macular degeneration (AMD) is a progressive inflammatory/ degenerative condition. There is no effective treatment for the more common dry form of AMD and it is our hope that iPS cell will provide an endless supply of RPE.
We have optimised simple and reproducible method which could be used as a starting point for a developing GMP protocols, a prerequisite for generating clinically relevant patient specific iPS cells.
We have established a protocol in deriving haematopoietic precursors to generate functional NK cells from iPS cells. We have also optimised a protocol in derivating hepatocyte-like cells from iPS cells.